Compare RGLD & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGLD | RVMD |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | United States | United States |
| Employees | N/A | 883 |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.2B | 19.2B |
| IPO Year | 1995 | N/A |
| Metric | RGLD | RVMD |
|---|---|---|
| Price | $230.49 | $140.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 19 |
| Target Price | ★ $262.17 | $140.84 |
| AVG Volume (30 Days) | 653.1K | ★ 3.7M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | ★ 32.74 | N/A |
| EPS | ★ 6.69 | N/A |
| Revenue | ★ $1,030,471,000.00 | N/A |
| Revenue This Year | $89.85 | N/A |
| Revenue Next Year | $5.05 | $533.02 |
| P/E Ratio | $34.81 | ★ N/A |
| Revenue Growth | ★ 43.24 | N/A |
| 52 Week Low | $150.75 | $34.00 |
| 52 Week High | $306.25 | $155.70 |
| Indicator | RGLD | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 33.10 | 60.59 |
| Support Level | $215.32 | $93.39 |
| Resistance Level | $235.52 | $155.70 |
| Average True Range (ATR) | 7.58 | 7.75 |
| MACD | -3.38 | -0.59 |
| Stochastic Oscillator | 1.48 | 36.30 |
Royal Gold Inc enquires and manages precious metal royalties and streams with a focus on gold. The company purchases a percentage of the metal produced from a mineral property for an initial payment without assuming responsibility for mining operations. Similarly, precious metal streams are purchase agreements with mine operators providing the right to purchase all or a portion of one or more metals produced from a mine in exchange for an upfront deposit payment. Generally, Royal Gold does not work on the properties in which it holds royalty and streaming assets. The company owns a portfolio of producing, development, evaluation, and exploration royalties and streams, and the majority of group revenue is generated from Canada, Mexico, Chile, and the United States.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.